Last reviewed · How we verify
ADP receptor inhibitors
ADP receptor inhibitors block the action of ADP on its receptor, preventing platelet activation and aggregation.
ADP receptor inhibitors block the action of ADP on its receptor, preventing platelet activation and aggregation. Used for Acute coronary syndrome, Myocardial infarction.
At a glance
| Generic name | ADP receptor inhibitors |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | ADP receptor inhibitor |
| Target | P2Y12 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
ADP receptor inhibitors work by binding to the P2Y12 receptor on platelets, which is responsible for platelet activation and aggregation. By blocking this receptor, ADP receptor inhibitors reduce the formation of blood clots and prevent platelet aggregation.
Approved indications
- Acute coronary syndrome
- Myocardial infarction
Common side effects
- Bleeding
- Thrombocytopenia
Key clinical trials
- Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors (PHASE2)
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer (PHASE2)
- CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer (PHASE2)
- A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer (PHASE2)
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (PHASE2)
- Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO) (NA)
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer (PHASE3)
- Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ADP receptor inhibitors CI brief — competitive landscape report
- ADP receptor inhibitors updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI